Star Therapeutics
Monoclonal antibodies for rare disease treatment
- Sector
- Biotech
- Latest Form D
- $125M, Oct 2025
- Total capital
- $125M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $125M
- 1 Form D · last Oct 2025
- 13 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- None on recordNo USPTO grants. Applications publish after 18 months.
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$125M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Adam RosenthalExecutive Officer, DirectorNamed in SEC Form D filings
- Amrit NagpalDirectorNamed in SEC Form D filings
- Beth SeidenbergDirectorNamed in SEC Form D filings
- Carl GordonDirectorNamed in SEC Form D filings
- Gary PatouExecutive OfficerNamed in SEC Form D filings
- Jason HaflerDirectorNamed in SEC Form D filings
Show all 12 people
- Maha KatabiDirectorNamed in SEC Form D filings
- Matthew FustDirectorNamed in SEC Form D filings
- Michelle CarpenterExecutive OfficerNamed in SEC Form D filings
- Nancy StaglianoDirectorNamed in SEC Form D filings
- Sandip PanickerExecutive OfficerNamed in SEC Form D filings
- Scott RobertsonExecutive OfficerNamed in SEC Form D filings
What it has protected
No granted patents are on record.
USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.
Checked: USPTO granted patents and published applications · Oct 23, 2026
Related companies, and why
- Sirnaomics, Inc.Similar federal contract value in Biotech · null in contracts
- Terrestrial Bio, Inc.Similar federal contract value in Biotech · null in contracts
- iTeos TherapeuticsSimilar federal contract value in Biotech · null in contracts
- NextPoint TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Quanta Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- UroGen Pharma Ltd.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .